Grace Therapeutics (GRCE) 10% Owner Inc. Buys $117K of Stock

By TradeTexts Research Desk Oct 26, 2026, 7:01 PM EDT

Key Points

Opaleye Management increased its ownership in Grace Therapeutics by 66,411 shares, bringing its total to 3,036,411 shares after the purchase.
As of October 26, 2026, Grace Therapeutics shares traded at $1.81, which is about equal to the closing price on the same day.
The healthcare company focuses on developing treatments for rare diseases, with a market cap of approximately $40.6 million.

Get Grace Therapeutics text alerts

We text you when insiders, Congress, analysts or big funds move on $GRCE.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Grace Therapeutics, Inc. alert may contain errors. Disclosures

On October 26, 2026, Opaleye Management Inc., a 10% owner of Grace Therapeutics, Inc. (GRCE), bought 66,411 shares for about $117,408. This purchase increased its stake by 2.24%, bringing its total shares to 3,036,411. The information comes from a Form 4 filing with the SEC.

Opaleye Management's recent buy adds to its previous insider trades, where it had made several purchases of Grace Therapeutics shares earlier in October. On October 9, it acquired 5,340 shares, followed by purchases of 7,215 shares on October 12, 23,485 shares on October 15, and 36,347 shares on October 16. These moves suggest a consistent interest in increasing its holdings in the company.

GRCE Grace Therapeutics, Inc.

$1.81 -50.55% year to date

Daily close · Oct 26, 2026

Insider trading track record

Opaleye Management Inc. vs. the S&P 500

YTD return +2.13% hypothetical

All-time return +2.13% S&P 500 +1.10%

vs. S&P 500 +1.03% ahead of the index

Hypothetical returns from Opaleye Management Inc.'s disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Grace Therapeutics

Cerity Partners LLC holds 849,055 shares of Grace Therapeutics, with a value of about $1.54 million. Eversept Partners, LP added 16,268 shares, increasing its total to 772,900 shares worth approximately $1.4 million. Citadel Advisors LLC boosted its stake by 250,999 shares, now holding 349,740 shares valued at about $633,029. Maven Securities Limited increased its position by 100,000 shares, totaling 200,000 shares worth around $362,000. Birchview Capital, LP also added 70,000 shares, bringing its total to 120,000 shares valued at about $217,199.

Grace Therapeutics, Inc. Stock Down 5.5%

As of October 26, 2026, Grace Therapeutics shares traded at $1.81, matching the closing price for the day. The stock is currently below its 50-day moving average by 13.8% and its 200-day moving average by 36.8%. Additionally, it is 65.1% below its 52-week high of $5.18, indicating the stock has seen significant downward pressure recently.

Recent Earnings

Grace Therapeutics has reported trailing twelve-month revenue of $0, with an EPS of -$1.17, indicating it is not currently profitable. The next earnings report is expected on November 14, 2026.

Insider Buying and Selling at Grace Therapeutics, Inc.

Opaleye Management Inc. has been active in buying shares of Grace Therapeutics in October 2026. Earlier, it purchased 5,340 shares on October 9 for about $10,918, followed by a buy of 7,215 shares on October 12 for around $14,574. On October 15, it added 23,485 shares at $45,685 and then 36,347 shares on October 16 for about $68,758. These trades show a consistent strategy to increase its stake in the company.

Bottom Line

Investors should watch for Grace Therapeutics' upcoming earnings report on November 14, 2026, for further insights into its financial health. With Opaleye Management's recent purchases, it will be interesting to see how this impacts shareholder sentiment moving forward.